Literature DB >> 7370960

Growth rate of 147 mammary carcinomas.

D von Fournier, E Weber, W Hoeffken, M Bauer, F Kubli, V Barth.   

Abstract

In 147 cases of mammary carcinoma, 388 serial mammographies were performed before final treatment. The average retrospective observation time was 27 months with a range of two months to 11 years. The number of serial mammographies per case ranged between two and 11. The tumor volume doubling times (TV); obtained by measuring the growth of the tumor nucleus shadow in the mammographies, ranged from 44 to 1869 days with an average of 212 days. No correlation between volume doubling time and histologic differentiation could be found. One hundred of these cancer patients were found in a screening population of 22,000 women receiving serial mammographies in a time period ranging from two to 16 years. An additional 40 cancer patients surfaced in this group without roentgenologic but with foregoing clinical or thermographic abnormalities before final diagnosis. An additional 21 cancer patients surfaced without any foregoing abnormalities. The follow-up tumor ranged between three months and two years with a mean time of one year and nine months. Not considering tumor size, pathologic-thermographic signs appeared with greater frequency the faster the tumor grew. Theoretically, an average of more than 16 years should elapse before an initial tumor cell develops into a 10-mm primary mammary carcinoma (30 doubling times). Therefore the length of time necessary for a 2-mm tumor to grow to a size of 10-mm is, on the average, four years.

Entities:  

Mesh:

Year:  1980        PMID: 7370960     DOI: 10.1002/1097-0142(19800415)45:8<2198::aid-cncr2820450832>3.0.co;2-7

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  37 in total

1.  Growth of Breast Cancer and Limited Surgery.

Authors: 
Journal:  Breast Cancer       Date:  1996-03-29       Impact factor: 4.239

Review 2.  AACR centennial series: the biology of cancer metastasis: historical perspective.

Authors:  James E Talmadge; Isaiah J Fidler
Journal:  Cancer Res       Date:  2010-07-07       Impact factor: 12.701

Review 3.  Geographical variation in endocrine function and its relation to breast cancer incidence: some general considerations.

Authors:  R D Bulbrook
Journal:  Breast Cancer Res Treat       Date:  1991-05       Impact factor: 4.872

4.  Patients' immune response to breast and lung carcinoma-associated Thomsen-Friedenreich (T) specificity.

Authors:  G F Springer; S M Murthy; P R Desai; W A Fry; H Tegtmeyer; E F Scanlon
Journal:  Klin Wochenschr       Date:  1982-02-01

5.  A contribution to the natural history of breast cancer. IV. Lobular carcinoma in situ and its relation to breast cancer.

Authors:  A H Tulusan; H Egger; M L Schneider; F Willgeroth
Journal:  Arch Gynecol       Date:  1982

Review 6.  Stem cells and the development of mammary cancers in experimental rats and in humans.

Authors:  P S Rudland
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

Review 7.  Moderate alcohol consumption and breast cancer in women: from epidemiology to mechanisms and interventions.

Authors:  Philip J Brooks; Samir Zakhari
Journal:  Alcohol Clin Exp Res       Date:  2012-10-16       Impact factor: 3.455

8.  Randomized study of mammography screening--preliminary report on mortality in the Stockholm trial.

Authors:  J Frisell; G Eklund; L Hellström; E Lidbrink; L E Rutqvist; A Somell
Journal:  Breast Cancer Res Treat       Date:  1991-03       Impact factor: 4.872

9.  Interval cancer and survival in a randomized breast cancer screening trial in Stockholm.

Authors:  J Frisell; A von Rosen; M Wiege; B Nilsson; S Goldman
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

10.  Mammographic screening and mortality from breast cancer: the Malmö mammographic screening trial.

Authors:  I Andersson; K Aspegren; L Janzon; T Landberg; K Lindholm; F Linell; O Ljungberg; J Ranstam; B Sigfússon
Journal:  BMJ       Date:  1988-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.